Sign In
Buy VKTX
$32.37
+1.99 (+6.55%)
At Close: Jun 22, 2026
Viking Therapeutics (VKTX) Up 1% Since Last Earnings Report: Can It Continue?
12:36pm, Friday, 21'st Nov 2025
Viking Therapeutics (VKTX) reported earnings 30 days ago. What's next for the stock?
3 Mid-Cap Growth Stocks That Have Mammoth Long-Term Potential
04:31am, Friday, 21'st Nov 2025
Mid-cap stocks can come with risks, but also a ton of upside in the long run. The stocks listed here offer exciting growth opportunities across multiple industries.
VKTX Completes Enrollment in First Late-Stage Study on Obesity Drug
12:36pm, Thursday, 20'th Nov 2025
Viking Therapeutics completes enrollment in its phase III VANQUISH-1 obesity study, surpassing targets and marking rapid progress for its VK2735 program.
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.
06:05am, Wednesday, 19'th Nov 2025
Eli Lilly has advanced in the triple-digits over three years, thanks to its weight loss drug portfolio. The following two biotech companies, due to the potential of their late-stage candidates, also c
Viking Therapeutics, Inc. (VKTX) Presents at Jefferies London Healthcare Conference 2025 Transcript
04:48am, Wednesday, 19'th Nov 2025
Viking Therapeutics, Inc. ( VKTX ) Jefferies London Healthcare Conference 2025 November 19, 2025 3:00 AM EST Company Participants Brian Lian - President, CEO & Director Conference Call Participants Ji
Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735
02:55am, Wednesday, 19'th Nov 2025
78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity Enrollment Completed Ahead of Schedule and Above Target Size, Indicating Strong Interest in VK2735 SAN DIEGO , Nov. 19, 2025 /PRNews
5AM Venture Just Dumped Its Viking Stake—Smart Call or Missed Opportunity?
02:11pm, Tuesday, 18'th Nov 2025
Exited entire position: down 189,593 shares, a net position change of $5.02 million No remaining shares held; post-trade stake is zero The position previously accounted for approximately 1.9% of the f
2 No-Brainer Healthcare Stocks to Buy Now
06:45am, Tuesday, 18'th Nov 2025
Pfizer's acquisition of obesity drugmaker Metsera positions the pharmaceutical giant to compete in a market expected to reach $130 billion by 2030. Viking Therapeutics has both injectable and oral ver
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?
10:31am, Wednesday, 12'th Nov 2025
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employe
2 Monster Stocks in the Making
04:45am, Monday, 10'th Nov 2025
Viking Therapeutics is developing innovative medicines in a fast-growing area. Axsome Therapeutics is generating strong sales, and solid regulatory progress could improve things.
Is There a Future for Viking Therapeutics?
06:55am, Sunday, 09'th Nov 2025
Viking has initiated an exciting new phase 1 study combining an oral and subcutaneous formulation of a weight loss drug. The phase 1 trial results are expected next year, with the Phase 3 (subcutaneou
Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek® 2025
07:05am, Thursday, 06'th Nov 2025
VENTURE Study Exploratory Analysis Shows VK2735 Improved Cardiometabolic Parameters After 13 Weeks; Reducing Prediabetes and Metabolic Syndrome SAN DIEGO , Nov. 6, 2025 /PRNewswire/ -- Viking Therapeu
Druckenmiller's Viking Trade Just Hit A Golden Cross — And A Sweet 36% Gain
10:01am, Wednesday, 05'th Nov 2025
Stanley Druckenmiller 's Viking Therapeutics Inc (NASDAQ:VKTX) bet is starting to look like a classic Druckenmiller move — quietly bold, impeccably timed, and now technically validated. The billiona
Here's Why Shares in Viking Therapeutics Shot Higher in October
05:15am, Wednesday, 05'th Nov 2025
Takeover speculation is rife in the industry, particularly with companies with promising obesity drug pipelines. Management reassured investors that there could be substantial value in its lead drug c
Stanley Druckenmiller has a fantastic investing track record, delivering a double-digit average annual return over time. The billionaire sold artificial intelligence (AI) leaders Nvidia and Palantir -
